EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Translational evaluation of Gelsectan ® effects on gut barrier dysfunction and visceral pain in animal models and irritable bowel syndrome with diarrhoea

Orsolya Inczefi iD, Hélène Eutamene, Fanny Placide, Valérie Tondereau, Petra Pallagi, Mária Bagyánszki, Nikolett Bódi, Nikolett Gémes, Gábor Szebeni, Tamás Molnár iD, Vassilia Theodorou, Richárd Róka

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Orsolya Inczefi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Centre for Gastroenterology, University of Szeged, Szeged, Hungary. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Rats, Wistar, Diarrhea, Disease Models, Animal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hungarian National Research, Development and Innovation Office, Devintec SAGL.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gelsectan ® is a formulation of xyloglucan (XG), pea protein, grape seed extract (PPGS) and xylo‐oligosaccharides (XOS). Our aim was to examine the effect of Gelsectan ® on rectal sensitivity in an animal model, abdominal pain in irritable bowel syndrome with diarrhoea (IBS‐D) subjects and intestinal permeability in both conditions.

Methods

Animals: Wistar rats received gavage with XOS, XG + PPGS or XG + PPGS + XOS, as a single dose or for 7 days before a partial restraint stress (PRS). Visceromotor response to rectal distension and total gut paracellular permeability to 51 Cr‐EDTA were assessed. Humans: IBS‐D and control patients were involved. After initial colonoscopy with biopsy sampling Gelsectan® was administered to IBS‐D patients for 12 weeks. Stool count and pain scores were documented. After treatment, colonoscopy was repeated. The permeability of biopsy samples was measured in Ussing‐chambers. Adherent mucus layer, Muc‐2 expression as well as TNFα, Interferon IFNγ were evaluated by histology/immunohistochemistry and ELISA assays, respectively.

Results

Animal studies: In control rats, PRS significantly increased visceromotor response as well as gut paracellular permeability. Single dose administration of XG + PPGS + XOS failed to reverse PRS, but 7 days of oral treatment reversed PRS‐induced rectal hypersensitivity and gut hyperpermeability. Human studies: Gelsectan ® treatment significantly reduced and abdominal pain. Intestinal permeability in IBS‐D patients was elevated compared with controls, Gelsectan ® restored permeability in the ascendent colon. Periodic acid–Schiff‐stained mucus layer was significantly thinner in IBS‐D patients compared with controls, In both segments, mucus thickness and the proportion of Muc‐2 positive cells were not affected by Gelsectan ® treatment. IFNγ tissue level in the sigmoid colon shows modest mucosal inflammation in IBS‐D.

Conclusions

Gelsectan ® prevented rectal hypersensitivity in rats, abdominal pain in human and intestinal hyperpermeability in rat and human studies respectively. These effects involve restoration of gut permeability. Based on this translational study, Gelsectan ® can be considered as an effective therapy for IBS‐D symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeRats, WistarDiarrheaDisease Models, AnimalXylansGlucansIntestinal MucosaPermeabilityAnimalsHumansRatsMaleFemaleAdultVisceral PainRectumMiddle AgedOligosaccharidesAbdominal Pain

Stichwörter der Autor:innen

Gelsectangut hyperpermeabilityirritable bowel syndromerectal hypersensitivity

Substanzen

XylansGlucansxyloglucanOligosaccharides

Autor:innen und Institutionen

  • Department of Medicine, Centre for Gastroenterology, University of Szeged, Szeged, Hungary.
  • UMR 1331, Toxalim (Research Centre in Food Toxicology), INRAE, Université de Toulouse III, ENVT, Toulouse, France.
  • Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary.
  • Laboratory of Functional Genomics, HUN-REN Biological Research Centre, Szeged, Hungary.
  • Department of Internal Medicine, Hematology Centre, Faculty of Medicine, University of Szeged, Szeged, Hungary.

ORCID-Profile: Orsolya Inczefi, Tamás Molnár

Förderung

  • Hungarian National Research, Development and Innovation Office
  • Devintec SAGL

Zitieren

APA

Inczefi, O., Eutamene, H., Placide, F., Tondereau, V., Pallagi, P., Bagyánszki, M., Bódi, N., Gémes, N., Szebeni, G., Molnár, T., Theodorou, V., & Róka, R. (2024). Translational evaluation of Gelsectan ® effects on gut barrier dysfunction and visceral pain in animal models and irritable bowel syndrome with diarrhoea. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12625

Vancouver

Inczefi O, Eutamene H, Placide F, Tondereau V, Pallagi P, Bagyánszki M, et al. Translational evaluation of Gelsectan ® effects on gut barrier dysfunction and visceral pain in animal models and irritable bowel syndrome with diarrhoea. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12625

BibTeX
@article{Inczefi2024,
  author = {Inczefi, Orsolya and Eutamene, Hélène and Placide, Fanny and Tondereau, Valérie and Pallagi, Petra and Bagyánszki, Mária and Bódi, Nikolett and Gémes, Nikolett and Szebeni, Gábor and Molnár, Tamás and Theodorou, Vassilia and Róka, Richárd},
  title = {Translational evaluation of Gelsectan ® effects on gut barrier dysfunction and visceral pain in animal models and irritable bowel syndrome with diarrhoea},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12625}
}
Kostenlos starten →